Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
208 results about "Human cytomegalovirus" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Human betaherpesvirus 5, sometimes called human cytomegalovirus (HCMV), is the type species of the virus genus Cytomegalovirus, which in turn is a member of the viral family known as Herpesviridae or herpesviruses. It is also commonly called CMV. Within Herpesviridae, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals.
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit human CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
Owner:THE TRUSTEES FOR PRINCETON UNIV
Human cytomegalovirus neutralising antibodies and use thereof
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
Owner:INSTITUTE FOR RESEARCH IN BIOMEDECINE
Human cytomegalovirus neutralising antibodies and use thereof
The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
Owner:HUMABS LLC
Human monoclonal antibody binding to human cytomegalovirus and its antigen binding portion
The present invention aims to provide a human monoclonal antibody and an antigen binding portion of a human monoclonal antibody with higher affinity and neutralizing capacity to the human cytomegalovirus (HCMV), a virus which causes various diseases in situations where immunodeficiencies are present. The current invention provides an anti-human cytomegalovirus (HCMV) monoclonal antibody which is a human monoclonal antibody capable of binding to HCMV and neutralizing bioactivity of the HCMV, and which may be further characterized as possessing a light chain (L chain) comprising an amino acid sequence of SEQ ID. NO. 1, and has a heavy chain (H chain) comprising an amino acid sequence of SEQ ID NO. 2.
Owner:EVEC +1
Cytomegalovirus surface protein complex for use in vaccines and as a drug target
Owner:THE TRUSTEES FOR PRINCETON UNIV
Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
InactiveUS20050019344A1Minimizing formulation difficultyReduce in quantityViral antigen ingredientsMicrobiological testing/measurementCtl epitopeVaccination
The present invention provides CTL epitope peptides and polyepitope peptides from 14 distinct antigens of human cytomegalovirus (HCMV) that are restricted through HLA the most commonly prevalent class I alleles in different ethnic populations of the world. These epitopes provide an important platform for CTL epitope-based vaccines against HCMV. The present invention further provides vaccine composiitons comprising the subject epitope and polyepitope peptides and methods for vaccination of humans and for the adoptive transfer of HCMV-specific T cells to human subjects. The present invention further provides reagents and methods for determining the HCMV status or level of HCMV-specific immunity of a subject.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
Detection of nucleic acids by multiple sequential invasive cleavages
The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. The present invention further relates to methods and devices for the separation of nucleic acid molecules based on charge. The present invention also provides methods for the detection of non-target cleavage products via the formation of a complete and activated protein binding region. The invention further provides sensitive and specific methods for the detection of human cytomegalovirus nucleic acid in a sample.
Owner:THIRD WAVE TECH
Recombinant human cytomegalovirus and vaccines comprising heterologous antigens
InactiveUS20090297555A1SsRNA viruses positive-senseViral antigen ingredientsHeterologousHeterologous Antigens
Owner:MEDIMMUNE LLC
DNA virus microRNA and methods for inhibiting same
InactiveUS20050222067A1Inhibiting microRNP activitySugar derivativesGenetic material ingredientsMicroRNAHuman cytomegalovirus
The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules.
Owner:THE ROCKEFELLER UNIV
Isolated human cytomegalovirus polypeptides and uses thereof
InactiveUS6120989APeptide/protein ingredientsAntibody mimetics/scaffoldsIgm antibodyHuman cytomegalovirus
Diagnostically relevant polypeptides and fusion proteins comprising an amino acid sequence which originates from cytomegalovirus and corresponds to a region of the major DNA-binding protein or of the C-terminal region of the tegument protein pp150 fused with at least one further fragment from another antigenic protein of cytomegalovirus are disclosed. The major DNA-binding protein is encoded by the reading frame UL57. The poly-peptides and fusion proteins according to the invention can be used in an advantageous manner in diagnostic tests and methods for the detection of IgM antibodies against cytomegalovirus.
Owner:BIOTEST SERUM INST GMBH
Immuno-reactive peptide CTL epitopes of human cytomegalovirus
The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8<+> class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLps in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Peptide and lipopeptide vaccines, with and without adjuvants, also are disclosed. Cellular vaccines comprising the peptides form a further embodiment of this invention.
Owner:CITY OF HOPE
Host targeted inhibitors of dengue virus and other viruses
ActiveUS20150166532A1Delay or minimize one or more symptoms associatedReduces and avoids symptom and causeBiocideOrganic chemistryHerpes simplex diseaseDisease injury
Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
Owner:DANA FARBER CANCER INST INC +1
Human cytomegalovirus neutralising antibodies and use thereof
The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
Owner:HUMABS LLC
Intravenous injection of cytomegalovirus human immunoglobulin and its preparation method
ActiveCN102286099ASteps to reduce precipitationKeep aliveImmunoglobulins against virusesAntiviralsEthanol precipitationAnion-exchange chromatography
The invention discloses a human cytomegalovirus immunoglobulin for intravenous injection and a preparation method thereof, and aims to improve the purity, yield and safety of the product. In the invention, the specific activity of the human cytomegalovirus immunoglobulin for intravenous injection is not less than 2.5 PEI-U / mg, the anti-CMV titer is not less than 100 PEI-U / ml, the purity is greater than 98.2%, and the protein content is 51-55 mg / ml. Caprylic acid precipitation and anion exchange chromatography are used instead of the partial ethanol precipitation step in the traditional low-temperature ethanol method, thereby keeping IgG in the supernate all the time so as to keep the IgG activity; and processes of caprylic acid virus inactivation and nano film virus removal are used, thereby effectively ensuring the safety of the product. Researches show that the preparation method disclosed by the invention improves the purity, yield and safety of the product, saves the energy and reduces the production cost.
Owner:SHENZHEN WEIGUANG BIOLOGICAL PROD
Human cytomegalovirus neutralizing antibodies and use thereof
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.
Owner:INSTITUTE FOR RESEARCH IN BIOMEDECINE
Human cytomegalovirus antigens expressed in MVA and methods of use
ActiveUS7163685B2Improve immunitySugar derivativesViral antigen ingredientsModified vaccinia AnkaraVaccine virus
DNA and protein constructs useful in producing vaccines against human cytomegalovirus contain optionally N-end modified and N-terminal ubiquitinated human cytomegalovirus antigenic proteins, including pp65, pp150, IE1, gB and antigenic fragments thereof. Vaccine viruses, in particular poxviruses such as vaccinia and Modified Vaccinia Ankara, that express the constructs may be used as vaccines to augment the immune response to human cytomegalovirus, both prophylatically and in patients already carrying human cytomegalovirus, as well as to create and expand cytomegalovirus-reactive T cells for transfer of adoptive immunity.
Owner:CITY OF HOPE
Monoclonal antibody capable of binding to specific discontinuous epitope occurring in ad1 region of human cytomegalovirus gb glycoprotein, and antigen-binding fragment thereof
The present invention provides a pharmaceutical composition for human cytomegalovirus HCMV causative of various disease states, the composition comprising a monoclonal antibody and an antigen-binding fragment thereof that specifically binds to the AD1 region of glycoprotein gB and that has excellent neutralizing capacity. The present invention provides: a monoclonal antibody and an antigen-binding fragment thereof having an excellent neutralizing capacity and cell-to-cell infection blocking capacity and specifically binding to a discontinuous sequence occurring in the HCMV AD1 region; a pharmaceutical composition comprising the antibody or the fragment thereof; and the like.
Owner:EVEC
Method for counting and segmenting viral particles in an image
ActiveUS20100151446A1Microbiological testing/measurementMaterial analysis by optical meansGeneticsHuman cytomegalovirus
The method is for intracellular counting and segmentation of viral particles in an image. An image is provided that has a plurality of items therein. A radius range of viral particles is determined. Round items in the image having a radius within the predetermined radius range are identified. Elliptical items that are formable from the predetermined radius range are determined. The round and elliptical items identified into groups are sorted. The viral particles among the round and elliptical items are identified. For example, the method may be used for intracellular counting and segmentation of siRNA treated human cytomegaloviral particles in TEM images.
Owner:INTELLIGENT VIRUS IMAGING
Human cytomegalovirus (HCMV) cytotoxic T cell epitopes, polyepitopes compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor
InactiveUS7524503B2Minimize difficultyReduce in quantityPeptide/protein ingredientsVirus peptidesCtl epitopeVaccination
The present invention provides CTL epitope peptides and polyepitope peptides from 14 distinct antigens of human cytomegalovirus (HCMV) that are restricted through HLA the most commonly prevalent class I alleles in different ethnic populations of the world. These epitopes provide an important platform for CTL epitope-based vaccines against HCMV. The present invention further provides vaccine compositions comprising the subject epitope and polyepitope peptides and methods for vaccination of humans and for the adoptive transfer of HCMV-specific T cells to human subjects. The present invention further provides reagents and methods for determining the HCMV status or level of HCMV-specific immunity of a subject.
Owner:COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
Host targeted inhibitors of dengue virus and other viruses
ActiveUS9879003B2Delay or minimize one or more symptoms associatedReduces and avoids symptom and causeOrganic chemistryHerpes simplex diseaseJunin virus
Novel antiviral compounds of Formulae (I)-(III) are provided: (I) (II) (III) The inventive compounds, pharmaceutical compositions thereof, and kits including the inventive compounds are useful for the prevention and treatment of infectious diseases caused by viruses, for example, by Flaviviridae virus (e.g., Dengue virus (DENY)), Kunjin virus, Japanese encephalitis virus, vesicular stomatitis virus (VSV), herpes simplex virus 1 (HSV-1), human cytomegalovirus (HCMV), poliovirus, Junin virus, Ebola virus, Marburg virus (MARV), Lassa fever virus (LASV), Venezuelan equine encephalitis virus (VEEV), or Rift Valley Fever virus (RVFV).
Owner:DANA FARBER CANCER INST INC +1
Fluorescent PCR detection method for human cytomegalovirus (HCMV)
InactiveCN101760560ASave time and reduce pollutionReduce pollutionMicrobiological testing/measurementFluorescent pcrHuman cytomegalovirus
The invention relates to a fluorescent PCR detection method for a human cytomegalovirus (HCMV). In the invention, two groups of detecting primers and probes are designed for UL122 and UL134 genes of a human cytomegalovirus (HCMV) genome. By detecting the two genes simultaneously, a false negative rate caused by the mutation of the HCMV genome is reduced. The technology of the invention can perform qualitative and quantitative detection on HCMV DNA quickly and conveniently and has relatively high specificity and sensitivity.
Owner:SHANGHAI FOSUN PHARMA (GROUP) CO LTD +1
Detection of nuceic acids by multiple sequential invasive cleavages
InactiveUS20080268455A1Easy to quantifyLeast riskSugar derivativesBacteriaNucleic acid sequencingHuman cytomegalovirus
The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. The present invention further relates to methods and devices for the separation of nucleic acid molecules based on charge. The present invention also provides methods for the detection of non-target cleavage products via the formation of a complete and activated protein binding region. The invention further provides sensitive and specific methods for the detection of human cytomegalovirus nucleic acid in a sample.
Owner:THIRD WAVE TECH
4-Hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
The present invention provide 4-hydroxyquinoline-3-carboxamide and hydrazide compounds of formula (I). These compounds are useful to treat or prevent the herpesviral infections, particularly, human cytomegaloviral infection.
Owner:PHARMACIA & UPJOHN CO
Primer group and probe group for detecting acute respiratory infectious diseases as well as application method and kit thereof
InactiveCN103993104AMicrobiological testing/measurementMicroorganism based processesDiseaseHuman cytomegalovirus
The invention provides a primer group for detecting acute respiratory infectious diseases. Causative agents include 14 types of causative agents of the respiratory infectious diseases, such as human cytomegalovirus and adenovirus. The primer group comprises any one or more than two groups of primers of the 14 types of causative agents. The invention also provides a probe group consisting of probes which are correspondingly paired with the primers in the primer group one by one, as well as an application method for applying the primer group and the probe group to liquid chip rapid detection methods. The application method can be used for detecting one or simultaneously detecting a plurality of causative agents of the acute respiratory infectious diseases, and also is high in sensitivity and good in specificity.
Owner:FUJIAN PROVINCIAL HOSPITAL +2
Internal-reference-containing HCMV fluorescence quantitative PCR detection kit
InactiveCN102115794AMonitor effectivenessReduce false negative rateMicrobiological testing/measurementFluorescence/phosphorescenceFluorescenceHuman cytomegalovirus
The invention relates to an internal-reference-containing human cytomegalovirus (HCMV) fluorescence quantitative polymerase chain reaction (PCR) detection kit. A detection primer and a detection probe are designed for a UL122 gene of an HCMV genome, a competitive internal reference amplification system is introduced by designing an internal reference probe and an internal reference male die and exists in the same reaction tube with an HCMV deoxyribonucleic acid (DNA) detection system, and the probability of false negative caused by the failure of the kit or experiment misoperation and the like can be effectively reduced by introducing the internal reference amplification system. The kit can perform qualitative and quantitative detection on HCMV DNA quickly and simply, and has high specificity and sensitivity.
Owner:SHANGHAI XINGYAO MED TECH DEV CO LTD +1
TCR for identifying human cytomegalovirus pp65 antigen
The invention relates to the technical field of T cell antigen receptors, in particular to TCR capable of identifying and combining with an HLA-A2-CMV-pp65495-503 antigen complex, a nucleotide sequence encoding the TCR or nucleic acid molecules of a complementary sequence of the nucleotide sequence, a carrier containing the nucleic acid molecules, cells transducing the nucleic acid molecules or carrier, a drug composition containing the TCR, the nucleic acid molecules, the carrier or the cells which are taken as active ingredients and application of the TCR, nucleic acid molecules, carrier, cells and drug composition which are used for preparing drugs for treating tumors or virus infection respectively.
Owner:深圳市因诺转化医学研究院 +1
Humanized single chain antibody for anti-human cytomegalovirus envelope glycoprotein
InactiveCN101054415ADoes not cause immune damageStrong specificityMetabolism disorderImmunoglobulins against virusesAnti virusSingle-Chain Antibodies
The present invention provides a human single strand antibody of resisting human cytomegalo virus envelope glycoprotein B characterized in that : it is expressed by protein first level sequence SEQ ID NO:1; it possesses character for identifying human cytomegalo virus envelope glycoprotein B and neutralizing activity for resisting human cytomegalo virus infection. The present invention also relates to nucleotide coding sequence corresponding to human single strand antibody sequence. The merit of the invention : The human single strand antibody for resisting human cytomegalo virus infection has not species difference to human, can not result in immune damage. The antibody is specific and has good binding ability and can serve as specific antibody drug for clinical anti-virus prophylaxis and treatment.
Owner:INST OF FIELD OPERATION SURGERY NO 3 MILITARY MEDICL UNIV PLA
PCR detection reagent kit for sexual disease mixed infection
InactiveCN1865451AStrong specificityMicrobiological testing/measurementImmunodeficiency virusOidiomycin
The invention discloses a synchronizing detection PCR agent box (hepatitis B virus, human immunodeficiency virus, human breast tumor virus, lues helicoid, human cytomegalovirus, simple herpesvirus, white oidiomycin, urea-dissolving mycoplasma, gonotoxin and Chlamydi trachomatis), which consists of blood type and secretion stains type. The user adds predisposed sample in the enlarging pipe to start enlarging reaction, which finishes detecting work simply and rapidly. The invention can detect ten venereal disease causal agents, which is fit for customs quarantine, prevailing monitor and hospital screen examination.
Owner:广州中医药大学热带医学研究所
Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens
The present invention relates to recombinant HCMV (human cytomegalovirus) expressing a pp65 polypeptide or fragment thereof fused to a heterologous or non-native polypeptide, in particular immunogenic and / or antigenic polypeptides. In particular, the heterologous gene products include antigenic or immunogenic polypeptides from a variety of pathogens, cellular genes, tumor antigens, and viruses. The recombinant viruses may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.
Owner:MEDIMMUNE LLC
Promoter System for Regulatable Gene Expression in Mammalian Cells
The present invention is directed to a bidirectional human cytomegalovirus (hCMV) promoter that can be used to promote transcription on both strands of a double stranded DNA molecule. When used as part of a system that includes tet operator and the gene coding for the tet repressor, the promoter can be used to induce mammalian gene expression in a highly regulated way.
Owner:THE BRIGHAM & WOMENS HOSPITAL INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com